Belgium's UCB Is Almost Over Its Patent Cliff, But Guides Revenues And Profits To Decline In 2012
This article was originally published in The Pink Sheet Daily
Executive Summary
UCB Pharma's trio of new products is managing, for now, to compensate for the generic erosion to its best-selling anti-epileptic Keppra.
You may also be interested in...
Epilepsy NMEs: A View Of The Playing Field
The late-stage pipeline for novel epilepsy treatments stars a handful of specialty and foreign firms, but the early-stage lineup makes room for new firms and the products of academic research. Venture philanthropy is a big factor, but the poor funding climate for CNS firms may limit play.
Epilepsy NMEs: A View Of The Playing Field
The late-stage pipeline for novel epilepsy treatments stars a handful of specialty and foreign firms, but the early-stage lineup makes room for new firms and the products of academic research. Venture philanthropy is a big factor, but the poor funding climate for CNS firms may limit play.
UCB’s Neupro Returns To U.S. Market With New Formulation, Indications
FDA approves a new version of UCB’s skin patch for treatment of advanced Parkinson’s disease and restless leg syndrome. The new product, which contains different excipients to prevent crystallization, will be available in July.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: